Wall Street Zen Upgrades HCW Biologics (NASDAQ:HCWB) to “Hold”

HCW Biologics (NASDAQ:HCWB) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Friday.

Separately, Maxim Group reduced their target price on HCW Biologics from $120.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, May 29th.

HCW Biologics Trading Up 1.5%

Shares of HCWB stock opened at $6.04 on Friday. HCW Biologics has a 12-month low of $5.00 and a 12-month high of $100.80. The stock’s 50-day moving average price is $8.00 and its 200-day moving average price is $13.06. The stock has a market capitalization of $8.69 million, a price-to-earnings ratio of -6.04 and a beta of 0.83.

HCW Biologics (NASDAQ:HCWB) last issued its earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%.

Insiders Place Their Bets

In related news, CFO Rebecca Byam acquired 8,462 shares of HCW Biologics stock in a transaction on Thursday, May 8th. The shares were bought at an average cost of $26.00 per share, with a total value of $220,012.00. Following the completion of the purchase, the chief financial officer now directly owns 43,010 shares of the company’s stock, valued at $1,118,260. The trade was a 24.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Lee Flowers bought 962 shares of the company’s stock in a transaction on Thursday, May 8th. The shares were acquired at an average price of $26.00 per share, with a total value of $25,012.00. Following the transaction, the senior vice president now directly owns 5,720 shares of the company’s stock, valued at approximately $148,720. This trade represents a 20.22% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 11,732 shares of company stock valued at $305,032 over the last ninety days. 42.70% of the stock is owned by insiders.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.